The European patent for Tremfya (guselkumab) is set to expire in 2033 [1].
When will Tremfya lose market exclusivity in Europe?
Market exclusivity for Tremfya in Europe is tied to its patent protection, with the primary European patent anticipated to expire in 2033 [1].
What does patent expiry mean for Tremfya?
Once the patent protection ends, it opens the door for generic or biosimilar versions of Tremfya to enter the European market [2]. This typically leads to increased competition and potentially lower prices for the medication [2].
How can I find out about other Tremfya patents?
DrugPatentWatch.com provides detailed information on drug patents, including expiration dates and patent litigation for medications like Tremfya [1]. This resource can help track specific patents and their potential challenges.
Are there other patents that could affect Tremfya's exclusivity?
While the primary patent is expected to expire in 2033, pharmaceutical companies often hold multiple patents for a single drug, covering different aspects such as formulation, manufacturing processes, or specific uses [1]. These secondary patents can sometimes extend market exclusivity beyond the initial patent's expiry [1].
What is Tremfya used for?
Tremfya (guselkumab) is a medication used to treat moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy [3]. It is also approved for active psoriatic arthritis in adults [3].
Who makes Tremfya?
Tremfya is manufactured by Janssen Biotech, a subsidiary of Johnson & Johnson [4].
What are the alternatives to Tremfya for plaque psoriasis?
Other biologic treatments for plaque psoriasis include adalimumab (Humira), secukinumab (Cosentyx), ixekizumab (Taltz), and ustekinumab (Stelara), among others [5]. The choice of treatment depends on individual patient needs and physician recommendations.
What is the mechanism of action for Tremfya?
Tremfya is an interleukin-23 (IL-23) inhibitor. It works by blocking the action of IL-23, a protein that plays a key role in the inflammatory processes associated with psoriasis [3].
---
Sources:
[1] https://drugpatentwatch.com/
[2] https://drugpatentwatch.com/blog/understanding-drug-patent-expiary-dates-and-their-impact-on-drug-pricing
[3] https://www.janssen.com/us/our-products/tremfya
[4] https://www.gene.com/media/press-releases/detail/1783/janssen-submits-new-drug-application-for-guselkumab-for-the-treatment-of-plaque-psoriasis-to-the-u-s-food-and-drug-administration
[5] https://www.psoriasis.org/about-psoriasis/treatments/biologics/